COMMUNIQUÉS West-GlobeNewswire

Kamada Announces Extension of GLASSIA® [Alpha1-Proteinase Inhibitor (Human)] Supply and Distribution Agreement with Takeda Through 2021 and Expected Transition of GLASSIA Manufacturing to Takeda
03/09/2019
Based on the Extended Term, Kamada Projects Revenues from Sales of GLASSIA to Takeda During 2019-2021 to be in the Range of $155 Million to $180 Million Based on Current GLASSIA U.S. Sales and Forecasted Growth, Kamada [...]
Ramy Ibrahim, M.D. to Join Surface Oncology Board of Directors
03/09/2019
Chief medical officer at Parker Institute for Cancer Immunotherapy to add immuno-oncology clinical development & industry leadership experience CAMBRIDGE, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Surface Oncology ( [...]
MediPharm Labs Enters into Agreements with Australian Licensed Producer & Forms Multiple Cannabis Supply Partnerships to Advance Australian Market Leadership
03/09/2019
Construction of New Melbourne-area Extraction Facility on Schedule Further Strengthens Australian Leadership Team Awarded Australian Cannabis Industry 2019 Innovation Award BARRIE, Ontario, Sept. 03, 2019 (GLOBE [...]
CROSSJECT : Point d'activité : Focus sur les avancées de l'été
03/09/2019
Communiqué de Presse Point d’activité : Focus sur les avancées de l’été Dijon, le 3 septembre 2019 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui développe et commercialisera prochainement un [...]
Autolus Announces Publication in Nature Medicine of Data Supporting the Development of AUTO1 for Treatment of Patients with ALL
03/09/2019
Findings from Phase I CARPALL Trial Demonstrate that Autolus’ Novel CAR T Therapy, AUTO1, Induces Enhanced Anti-tumor Response Without Severe Cytokine Release Syndrome 86% molecular complete response rate after a single [...]
Verona Pharma to Present at H.C. Wainwright 21st Annual Global Investment Conference
03/09/2019
LONDON, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that Piers Morgan, CFO, [...]
Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/Diabetes
03/09/2019
Zealand Pharma company announcement – No. 29 / 2019 The dual acting GLP-1/glucagon peptide BI 456906 is a part of Boehringer Ingelheim’s pipeline portfolio in obesity and diabetes The Phase 2 trial for BI 456906 is [...]
Sandoz announces global deal to commercialize proposed biosimilar natalizumab, a key multiple sclerosis medicine
03/09/2019
Worldwide agreement with Polpharma gives Sandoz commercialization rights to proposed biosimilar natalizumab for relapsing-remitting multiple sclerosis (RRMS) RRMS affects ~85% of MS patients and can create a substantial [...]
ObsEva Reports New Clinical Evidence of Nolasiban Mechanism of Action, Supporting Its Potential to Increase Live Birth Rate Following Embryo Transfer in IVF
03/09/2019
Results show decreased uterine contractions, increased endometrial blood flow and gene expression relevant for uterine receptivity to implantation 4Q:19 Read-out confirmed for Phase 3 IMPLANT 4 trial of ObsEva’s novel [...]
argenx to Present at Morgan Stanley 17th Annual Global Healthcare Conference
03/09/2019
September 3, 2019 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the [...]
Santhera Announces Financial Results for the First Half-Year 2019
03/09/2019
A conference call will be held today at 13:00 CEST, 12:00 BST, 07:00 EDT. Details are at the end of this statement. Pratteln, Switzerland, September 3, 2019 – Santhera Pharmaceuticals (SIX: SANN) reports first half-year [...]
Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.
03/09/2019
Basel, 3 September 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced that Roche has extended the offering period of its previously announced tender offer to [...]
Afya Limited Issues Guidance for 2nd Half of 2019
03/09/2019
On-track to Deliver 2019 Pro Forma Adjusted EBITDA above R$300 million NOVA LIMA, Brazil, Sept. 02, 2019 (GLOBE NEWSWIRE) -- Afya Limited, or Afya (Nasdaq: AFYA), today issued guidance for results for the second half of [...]
PROJECT HOPE GETS READY FOR HURRICANE DORIAN
02/09/2019
Project HOPE lines up medical team and health supplies to deploy in Category 5 storm’s aftermath Millwood, Virginia, Sept. 02, 2019 (GLOBE NEWSWIRE) -- As Hurricane Dorian makes its way to the United States, the global [...]
GENFIT: Board of Directors, Represented by Chairman Jean-François Mouney, Appoints Pascal Prigent as New CEO
02/09/2019
GENFIT: Board of Directors, Represented by Chairman Jean-François Mouney, Appoints Pascal Prigent as New CEO Lille (France), Cambridge (Massachusetts, United States), September 2, 2019 – GENFIT (Nasdaq and Euronext: [...]
GENFIT : Au nom du Conseil d’Administration, son Président Jean-François Mouney annonce la nomination de Pascal Prigent au poste de nouveau Directeur Général
02/09/2019
GENFIT : Au nom du Conseil d’Administration, son Président Jean-François Mouney annonce la nomination de Pascal Prigent au poste de nouveau Directeur Général Lille (France), Cambridge (Massachusetts, États-Unis), le 2 [...]
Össur hf: Transactions in relation to share buyback program
02/09/2019
Announcement no. 50/2019 2 September 2019 Transactions in relation to share buyback program On 14 May 2019, Össur hf. initiated a share buy-back program, see Company announcement no. 31/2019. The purpose of the share [...]
Information on total number of voting rights and shares composing the share capital as at August 31st, 2019
02/09/2019
Paris, September 2 nd , 2019 – 6.00PM CET - Pixium Vision (FR0011950641 - PIX), a bioelectronic company developing innovative bionic vision systems to allow patients who have lost their sight to lead more independent [...]
Information relative au nombre total de droits de vote et d’actions composant le capital social au 31 août 2019
02/09/2019
Paris, le 2 septembre 2019 – 18 :00 CET - Pixium Vision (FR0011950641 - PIX), société bioélectronique qui développe des systèmes de vision bionique innovants pour permettre aux patients ayant perdu la vue, de vivre de [...]

Pages